Appointment of Dr Otto Schwarz as Independent Director and Chairman of the Board
Zug, Switzerland, December 4, 2019 – Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on bringing…
SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy
Approval based on pivotal trials that assessed the efficacy and safety of cenobamate Arvelle Therapeutics has exclusive rights to develop and…
Arvelle Therapeutics wins Series A Finance Raise of the Year Award
Zug, Switzerland, November 20, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to…
Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology
Cenobamate significantly reduced focal seizure frequency, with as many as 20% of patients reaching zero seizures during the study’s maintenance…
Arvelle Therapeutics Strengthens Management Team with Key New Hires
Appoints Petra Molan as Senior Vice President Commercial and Enrico Dolfini as Vice President Legal Counsel Full leadership team now in place ahead…
Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe
Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million A…